OssDsign selected as one of the Nordic region’s 50 leading companies of the future

Report this content

Today, the top 50 future companies in the Techarenan Challenge 2020 were announced and OssDsign has been named one of the finalists in the competition that companies from all over the Nordic region have applied for.

The Techarenan Challenge, arranged for the seventh year, is open to all Swedish and Nordic companies in the startup and growth phase regardless of the industry. The competition is aimed at all companies with a unique innovation or business concept holding the potential for global commercialization. The companies have been evaluated by an expert jury where great focus has been on scalability, sustainability and well-defined growth opportunities.

"This year's final field is one of the strongest so far in terms of both breadth and apex. It is obvious that Sweden and the Nordic countries are a breeding ground for exceptional entrepreneurs and companies. Many of the companies have already gained a foothold internationally and have created a strong position for further expansion, " says Omid Ekhlasi, Founder and Competition Manager Techarenan.

"We are very pleased to have been selected as one of the foremost future companies in the Nordic countries and we look forward to the semi-final of the Techarenan Challenge on November 13 in Stockholm," says Anders Lundqvist, CEO of OssDsign.

For more information on Techarenan Challenge 2020 visit: https://techarenan.se/challenge/ (in Swedish)


For further information, please contact:

Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08
Email: al@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.